Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

Do fibrates truly preserve kidney function?

Nature Reviews Endocrinology volume 7, pages 130–131 (2011)Cite this article

Subjects

Despite the many advances in understanding and treating diabetes mellitus and diabetes-related kidney disease, progression of nephropathy, which ultimately leads to end-stage kidney disease, remains unstoppable. In the FIELD study, Davis et al. assert that long-term fenofibrate treatment in patients with type 2 diabetes mellitus might resolve this problem.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. United States Renal Data System. USRDS 2010 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States [online], http://www.usrds.org/atlas.htm (2010).

  2. Retnakaran, R. et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55, 1832–1839 (2006).

    Article  CAS  Google Scholar 

  3. Lewis, E. J. et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

    CAS  Google Scholar 

  4. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).

    Article  CAS  Google Scholar 

  5. Strippoli, G. F. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645–651 (2008).

    Article  CAS  Google Scholar 

  6. Angeles, C., Lane, B. P., Miller, F. & Nord., E. P., Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am. J. Kidney Dis. 44, 543–550 (2004).

    Article  Google Scholar 

  7. Ansquer, J. C. et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am. J. Kidney Dis. 51, 904–913 (2008).

    Article  CAS  Google Scholar 

  8. Davis, T. M. et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54, 280–290 (2011)

    Article  CAS  Google Scholar 

  9. Landray, M. J. et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am. J. Kidney Dis. 38, 537–546 (2001).

    Article  CAS  Google Scholar 

  10. Drury, P. L. et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54, 32–43 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. G. L. Bakris gbakris@gmail.com

Authors and Affiliations

  1. Nephrology Section, Endocrinology Section, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, MC 1027, Chicago, 60637, IL, USA

    Suneel M. Udani

  2. Hypertensive Diseases Unit, Endocrinology Section, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, MC 1027, Chicago, 60637, IL, USA

    George L. Bakris

Authors
  1. Suneel M. Udani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

G. L. Bakris serves on a Data Safety Monitoring Board of a fibrate trial funded by Abbott and is a consultant to Merck. S. Udani declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Udani, S., Bakris, G. Do fibrates truly preserve kidney function?. Nat Rev Endocrinol 7, 130–131 (2011). https://doi.org/10.1038/nrendo.2011.14

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.14

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing